HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation

Objective To compare hepatitis C virus (HCV) RNA levels from serum and explanted native liver samples from patients undergoing living donor liver transplantation (LDLT). Methods This was a prospective observational study. Serum and liver samples were collected from consecutive serum anti-HCV-positive transplant recipients between February 2016 to August 2019. HCV RNA was extracted from liver samples and subjected to one-step reverse-transcription qPCR. using the TopScript One Step qRT-PCR Probe Kit with HCV qPCR probe assay and human GAPDH qPCR probe assay on a ViiA7 Real-Time PCR System. Results Among the 80 patients, 36% (29/80) were HCV RNA positive in serum and 85% (68/80) had positive hepatic HCV RNA. Post-liver transplantation, 4% (3/80) patients were serum positive. Conclusions Our study suggests that pre-transplant serum HCV RNA levels may give an underestimate of the number of positive HCV RNA cases and that hepatic HCV RNA data may be more accurate.

[1]  Ming‐Lung Yu,et al.  Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy , 2020, Clinical and molecular hepatology.

[2]  M. Ghany,et al.  Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection , 2020 .

[3]  C. Quintini,et al.  Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience , 2020, Hepatology.

[4]  A. Singal,et al.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. , 2019, Gastroenterology.

[5]  Hannah M. Lee,et al.  Updates on Chronic HBV: Current Challenges and Future Goals , 2019, Current Treatment Options in Gastroenterology.

[6]  Ming‐Lung Yu,et al.  Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study , 2019, BMJ Open.

[7]  A. Gasbarrini,et al.  Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  K. Kerr,et al.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.

[9]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[10]  J. O. Phillips,et al.  High-density functional-RNA arrays as a versatile platform for studying RNA-based interactions , 2018, Nucleic acids research.

[11]  T. Nakano,et al.  Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation , 2016, PloS one.

[12]  E. Schiff,et al.  Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. , 2015, Gastroenterology.

[13]  N. Chavez-Tapia,et al.  Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .

[14]  N. Terrault Hepatitis C therapy before and after liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  J. Pawlotsky,et al.  Standardization of Hepatitis C Virus RNA Quantification , 2000, Hepatology.